Description
In this informative presentation, Professor Xavier Griffin from Barts and Queen Mary discusses two critical clinical trials, TiLLi and Direct, focusing on venous thromboembolism (VTE) prophylaxis. He explains the relevance of VTE prophylaxis studies, tracing their importance back to a significant research recommendations document developed by orthopedic surgeons and NICE seven years ago. These studies were highlighted by patients as key research uncertainties they wanted addressed.
Xavier highlights the TiLLi trial, which is nearing launch, aimed at adults with lower limb immobilization due to injury. The trial seeks to determine the efficacy of Direct Oral Anticoagulants (DOACs) versus low molecular weight heparin or no drug in reducing bleeding and clotting complications. He outlines that this trial plans to recruit about 10,000 patients from various hospitals across the UK.
The Direct trial, which focuses on hip fractures, is still in the setup phase and aims to compare the effects of aspirin and low molecular weight heparin on patient outcomes. This trial adopts a cluster randomization model, simplifying participation for hospitals by allowing them to administer the allocated treatment as standard practice.
Professor Griffin emphasizes the ease of participation, stating that no individual patient consent is needed, as the trial will utilize routine clinical data. He urges all attendees to get involved and highlights the ambitious goals, inviting volunteers through a QR code for email registration to support these important clinical efforts.